Grb10 is involved in BCR-ABL-positive leukemia in mice

[1]  L. Rönnstrand,et al.  FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia , 2013, Molecular oncology.

[2]  N. Turner,et al.  Grb10 regulates the development of fiber number in skeletal muscle , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  I. Flinn,et al.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.

[4]  C. Miething,et al.  An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis. , 2011, Blood.

[5]  Elaine Coustan-Smith,et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.

[6]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[7]  S. Shurtleff,et al.  Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Esparís-Ogando,et al.  ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy , 2009, PloS one.

[9]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Bokemeyer,et al.  Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. , 2008, Blood.

[11]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[12]  C. Stewart,et al.  Grb10 and Active Raf-1 Kinase Promote Bad-dependent Cell Survival* , 2007, Journal of Biological Chemistry.

[13]  Florentia M. Smith,et al.  Mice with a Disruption of the Imprinted Grb10 Gene Exhibit Altered Body Composition, Glucose Homeostasis, and Insulin Signaling during Postnatal Life , 2007, Molecular and Cellular Biology.

[14]  B. Brors,et al.  Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase , 2007, Leukemia.

[15]  Susan O'Brien,et al.  Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. , 2007, Blood.

[16]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[17]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[18]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[19]  F. Lordick,et al.  The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib , 2006, Leukemia.

[20]  G. Daley,et al.  Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy , 2006, Cancer.

[21]  S. Armstrong,et al.  Gene Expression Profiling Identifies BAX-δ as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia , 2005 .

[22]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[23]  S. Elledge,et al.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  O. Kawanami,et al.  Up-regulation of growth factor receptor-bound protein 10 in cervical squamous cell carcinoma. , 2005, Oncology reports.

[25]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[26]  J. Miguel,et al.  Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia , 2005, Leukemia.

[27]  W. Bornmann,et al.  A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. , 2005, Blood.

[28]  E. Van Obberghen,et al.  Grb10 Prevents Nedd4-mediated Vascular Endothelial Growth Factor Receptor-2 Degradation* , 2004, Journal of Biological Chemistry.

[29]  D. Neuberg,et al.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Vihinen,et al.  Changes in apoptosis-related pathways in acute myelocytic leukemia. , 2003, Cancer genetics and cytogenetics.

[31]  C. Eaves,et al.  Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. , 2003, Blood.

[32]  Youping Deng,et al.  Growth Factor Receptor-binding Protein 10 (Grb10) as a Partner of Phosphatidylinositol 3-Kinase in Metabolic Insulin Action* , 2003, Journal of Biological Chemistry.

[33]  Florentia M. Smith,et al.  Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Slovak,et al.  Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. , 2003, Blood.

[35]  P. Dent,et al.  Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  T. Skorski,et al.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571 , 2002, Oncogene.

[37]  Eric J Wagner,et al.  Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. , 2002, Molecular cell.

[38]  H. Iwasaki,et al.  Critical role for Gab2 in transformation by BCR/ABL. , 2002, Cancer cell.

[39]  C. Peschel,et al.  Role for the Adaptor Protein Grb10 in the Activation of Akt , 2002, Molecular and Cellular Biology.

[40]  P. Pandolfi,et al.  P62dok, a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210bcr-abl , 2001, The Journal of experimental medicine.

[41]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[42]  W. R. Bishop,et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. , 2001, Blood.

[43]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[44]  F. Liu,et al.  Identification of Grb10 as a direct substrate for members of the Src tyrosine kinase family , 2000, Oncogene.

[45]  George Q. Daley,et al.  The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.

[46]  Jean Y. J. Wang,et al.  The SH2-containing adapter protein GRB10 interacts with BCR-ABL , 1998, Oncogene.

[47]  David Y. Thomas,et al.  Interaction of the Grb10 Adapter Protein with the Raf1 and MEK1 Kinases* , 1998, The Journal of Biological Chemistry.

[48]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[49]  G. Zon,et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. , 1995, Blood.

[50]  N. Sonenberg,et al.  Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling , 2011 .

[51]  M. Gordon.  Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .

[52]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[53]  S. Armstrong,et al.  Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. , 2005, Cancer research.

[54]  B. Cullen,et al.  Use of RNA polymerase II to transcribe artificial microRNAs. , 2005, Methods in enzymology.

[55]  P. Pandolfi,et al.  62 dok , a Negative Regulator of Ras and Mitogen-activated Protein Kinase ( MAPK ) Activity , Opposes Leukemogenesis by p 210 bcr-abl , 2001 .

[56]  R. A. Etten.  Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice. , 2001 .